疫苗诱导免疫性血栓性血小板减少症中血小板因子4抗体的持续性与长期致病性
该研究探讨VITT患者抗PF4抗体持久性是否源于急性期抗体克隆持续或表位扩展产生新抗体。6例Ad26.COV2.S相关VITT患者中位随访244天,另1例ChAdOx1 nCoV-19相关VITT患者急性期后>4年检测。结果显示抗PF4抗体为单/寡克隆且丰度随时间下降,无新抗体产生证据;1例患者抗体为kappa轻链;6例Ad26.COV2.S相关VITT患者无长期血小板减少/血栓,但1例ChAdOx1 nCoV-19相关VITT患者4年后仍有血小板活化抗PF4抗体伴慢性低度血小板减少。
要点
- VITT抗PF4抗体持久性源于急性期克隆持续,非表位扩展产生新抗体。
- VITT抗体可为lambda或kappa轻链,不限于lambda轻链。
- 部分VITT患者急性事件多年后仍可存在血小板活化抗体和血小板减少。
核心结论
- VITT不同于血栓意义单克隆丙种球蛋白病,表现为意义未明单克隆丙种球蛋白病阴性状态,但需更大研究确认。
- VITT抗体可由lambda或kappa轻链组成,部分患者急性事件多年后仍表现持续性血小板减少。
研究设计与样本
- 研究6例Ad26.COV2.S相关VITT患者样本,中位随访244天(范围114-664天),用抗原/功能试验和质谱研究。
- 另1例ChAdOx1 nCoV-19相关VITT患者在急性表现后>4年检测。
主要发现
- 亲和富集抗PF4抗体后,尽管天然血清蛋白电泳/「Mass-Fix」检测阴性,仍观察到单/寡克隆抗PF4抗体。
- 抗PF4抗体丰度随时间下降,急性表现后无新抗PF4抗体产生证据。
- 1例VITT患者产生kappa轻链抗体,而既往研究提示VITT抗体与lambda轻链 stereotypical 配对。
- 6例Ad26.COV2.S相关VITT患者未见长期血小板减少/血栓。
- 另1例ChAdOx1 nCoV-19相关VITT患者急性事件4年后见血小板活化抗PF4抗体,伴慢性低度血小板减少。
临床怎么用
- VITT患者急性期后抗PF4抗体可持续存在,但丰度随时间下降,无需因抗体持续而长期抗凝。
- 对VITT后多年仍血小板减少者,应评估血小板活化抗PF4抗体。
局限性
- 结论需更大规模研究确认。
- 样本量小(6例Ad26.COV2.S相关VITT和1例ChAdOx1 nCoV-19相关VITT)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a transient prothrombotic process, although recent data suggest that VITT anti-platelet factor 4 (PF4) antibodies are more persistent than those in heparin-induced thrombocytopenia. OBJECTIVES: We sought to interrogate whether anti-PF4 antibody persistence in VITT is related to the continued persistence of antibody clones from the acute phase or to the development of novel anti-PF4 antibodies due to epitope spreading. METHODS: Samples from 6 patients with Ad26.COV2.S-associated VITT with a median time to follow-up of 244 days from acute presentation (range, 114-664 days) were studied in antigenic/functional assays and by mass spectrometry. One patient with ChAdOx1 nCoV-19-associated VITT was tested >4 years after acute presentation. RESULTS: Upon affinity-enrichment of anti-PF4 antibodies, mono/oligoclonal anti-PF4 antibodies were observed despite negative results in serum protein electrophoresis/"Mass-Fix" testing of native sera. Anti-PF4 antibody abundance decreased over time, with no evidence of novel anti-PF4 antibody production after acute presentation. Although previous studies indicate a stereotypical pairing of VITT antibodies with lambda light chains, 1 patient with VITT produced antibodies with a kappa light chain. Long-term thrombocytopenia/thrombosis was not seen in any of the 6 Ad26.COV2.S-associated VITT patients; however, platelet-activating anti-PF4 antibodies were seen 4 years after the acute event in an additional patient with ChAdOx1 nCoV-19-associated VITT with chronic low-grade thrombocytopenia. CONCLUSION: VITT, unlike monoclonal gammopathy of thrombotic significance, appears to be a monoclonal gammopathy of unknown significance-negative state, but it needs confirmation in larger studies. VITT antibodies can be composed of lambda or kappa light chains, and some patients with VITT exhibit persistent thrombocytopenia many years after the acute event.
引用
- Kanack A, Mauch E, Roberge G, et al. Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia. J Thromb Haemost. 2026. PMID: 41936925. doi:10.1016/j.jtha.2026.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。